Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
US food allergies specialist Aimmune Therapeutics yesterday announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in the firm to date to $473 million. 6 February 2020
Biotechnology
Shares of US biotech major Gilead Sciences on Wednesday fell as much as 4.9% after the company revealed that its request for an inter partes review (IPR) by the US Patent and Trademark Office (USPTO) of patents granted to the US Department of Health and Human Services (HHS) for HIV pre-exposure prophylaxis (PrEP). 6 February 2020
Biotechnology
AbbVie today announced positive top-line results from the Phase III SELECT-PsA 1 clinical trial of its Rinvoq (upadacitinib), which was approved by the US Food and Drug Administration last August and in Europe in December, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). 5 February 2020
Biotechnology
Aimmune Therapeutics today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb 7195 from Californian monoclonal antibody specialist Xencor. 5 February 2020
Biotechnology
California, USA-based clinical-stage biotech CODA Biotherapeutics today announced it has completed the acquisition of Attenua. Financial terms of the transaction are not being disclosed. 5 February 2020
Biotechnology
Shares in Gilead Sciences were down in pre-market trading on Wednesday following the company’s presentation of its annual and fourth-quarter 2019 financial results late Tuesday. 5 February 2020
Biotechnology
A new biotech dubbed Anteros Pharmaceuticals has been launched by the drug development accelerator BioMotiv, together with Bristol-Myers Squibb (NYSE: BMY). 4 February 2020
Biotechnology
US biopharma Insmed closed 41% up on Monday. 4 February 2020
Biotechnology
The UK’s Healx, an AI-powered and patient-inspired technology company, today announced the appointment of Dr Anthony Hall as chief medical officer (CMO). 4 February 2020
Biotechnology
East Coast, USA-based lung specialist United Therapeutics has announced negative top-line results from the Phase II/III DISTINCT study of Unituxin (dinutuximab). 4 February 2020
Biotechnology
New Jersey, USA-based PTC Therapeutics has announced real-world data showing a positive impact from the use of Translarna (ataluren), a protein restoration therapy. 3 February 2020
Biotechnology
A new Sanofi survey has found that only 6% of cardiologists are currently prescribing PCSK9 blockers, while 97% say they are satisfied with outcomes from these treatments. 3 February 2020
Biotechnology
US clinical-stage biotech firm Boston Pharmaceuticals has appointed Dr Craig Basson as its chief medical officer. 3 February 2020
Biotechnology
London-listed Affimer developer Avacta has signed a collaboration and license agreement with AffyXell Therapeutics, a new joint venture formed together with Daewoong Pharmaceutical. 3 February 2020
Biotechnology
Israeli drugmaker Teva Pharmaceutical Industries and its partner for the Japanese market, Otsuka Pharmaceutical, have edged closer to approval for Ajovy (fremanezumab) in the Asian country. 3 February 2020
Biotechnology
Shares of US biopharma firm Orgenesis rocketed more than 35% to $6.77 in pre-market trading today, after announcing that Catalent has agreed to acquire MaSTherCell Global, a contract development manufacturing organization (CDMO) subsidiary of Orgenesis, which is also backed by Great Point Partners and SFPI-FPIM. 3 February 2020
Biotechnology
The European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for belantamab mafodotin in relapsed or refractory multiple myeloma whose prior therapy included an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody. 3 February 2020
Biotechnology
New Jersey, USA-based oncology giant Bristol-Myers Squibb has withdrawn a European application to market Opdivo (nivolumab) and Yervoy (ipilimumab) for certain people with advanced non-small cell lung cancer (NSCLC). 3 February 2020
Biotechnology
Shares in US biotech Gilead Sciences were up by 12% in pre-market on Monday. 3 February 2020
Biotechnology
On Friday, the US Food and Drug Administration approved Palforzia (Peanut [Arachis hypogaea] allergen powder-dnfp) as the first ever treatment for patients with peanut allergy. 1 February 2020
All news
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze